Stryker Corporation $SYK Shares Sold by Peachtree Investment Partners LLC

Peachtree Investment Partners LLC lessened its position in Stryker Corporation (NYSE:SYK) by 39.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,692 shares of the medical technology company’s stock after selling 1,752 shares during the period. Peachtree Investment Partners LLC’s holdings in Stryker were worth $847,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new position in Stryker during the fourth quarter worth about $26,000. Sankala Group LLC bought a new stake in Stryker in the fourth quarter worth about $26,000. United Financial Planning Group LLC acquired a new stake in Stryker in the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. acquired a new stake in Stryker in the 4th quarter valued at about $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker during the 4th quarter valued at about $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. UBS Group started coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price on the stock. Robert W. Baird set a $385.00 target price on shares of Stryker in a report on Friday, May 1st. Citizens Jmp decreased their price target on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 price target on shares of Stryker in a report on Friday, May 1st. Finally, Argus set a $370.00 price objective on Stryker in a research report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Price Performance

NYSE SYK opened at $338.80 on Monday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a market cap of $129.95 billion, a PE ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76. The stock’s 50-day moving average price is $324.61 and its two-hundred day moving average price is $333.40.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the firm posted $3.13 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.